Tyrosine kinase inhibitors (TKIs) target angiogenesis by affecting, for example, the VEGF receptors in tumors and have improved outcomes for patients with metastatic renal cell carcinoma (mRCC). Immune checkpoint inhibitors (ICIs) have also been proposed for treatment of mRCC with encouraging results. A better understanding of the activity of immune cells in mRCC, the immunomodulatory effects of TKIs, and the characteristics defining patients most likely to benefit from various therapies will help optimize immunotherapeutic approaches. In this study, we investigated the influence of the TKI pazopanib on dendritic cell (DC) performance and immune priming. Pazopanib improved DC differentiation and performance by promoting upregulation of thematuration markers HLA-DR, CD40 and CCR7; decreasing IL10 production and endocytosis; and increasing T-cell proliferation. PD-L1 expression was also downregulated. Our results demonstrate that pazopanib inhibits the Erk/b-catenin pathway, suggesting this pathway might be involved in increased DC activation. Similar results were confirmed in DCs differentiated from mRCC patients during pazopanib treatment. In treated patients pazopanib appeared to enhance a circulating CD4þ T-cell population that expresses CD137 (4-1BB). These results suggest that a potentially exploitable immunomodulatory effect induced by pazopanib could improve responses of patients with mRCC in customized protocols combining TKIs with ICI immunotherapy

TK inhibitor pazopanib primes DCs by downregulation of the β-catenin pathway / Zizzari, ILARIA GRAZIA; Napoletano, Chiara; Botticelli, Andrea; Caponnetto, Salvatore; Calabro', Fabio; Gelibter, ALAIN JONATHAN; Rughetti, Aurelia; Ruscito, Ilary; RAHIMI KOSHKAKI, Hassan; Ernesto, Rossi; Giovanni, Schinzari; Marchetti, Paolo; Nuti, Marianna. - In: CANCER IMMUNOLOGY RESEARCH. - ISSN 2326-6066. - STAMPA. - 6:6(2018), pp. 711-722. [10.1158/2326-6066.CIR-17-0594]

TK inhibitor pazopanib primes DCs by downregulation of the β-catenin pathway

Ilaria Grazia Zizzari
Primo
;
Chiara Napoletano
Secondo
;
Andrea Botticelli;Salvatore Caponnetto;CALABRO', Fabio;GELIBTER, ALAIN JONATHAN;Aurelia Rughetti;Ilary Ruscito;Hassan Rahimi;Paolo Marchetti
Penultimo
;
Marianna Nuti
Ultimo
2018

Abstract

Tyrosine kinase inhibitors (TKIs) target angiogenesis by affecting, for example, the VEGF receptors in tumors and have improved outcomes for patients with metastatic renal cell carcinoma (mRCC). Immune checkpoint inhibitors (ICIs) have also been proposed for treatment of mRCC with encouraging results. A better understanding of the activity of immune cells in mRCC, the immunomodulatory effects of TKIs, and the characteristics defining patients most likely to benefit from various therapies will help optimize immunotherapeutic approaches. In this study, we investigated the influence of the TKI pazopanib on dendritic cell (DC) performance and immune priming. Pazopanib improved DC differentiation and performance by promoting upregulation of thematuration markers HLA-DR, CD40 and CCR7; decreasing IL10 production and endocytosis; and increasing T-cell proliferation. PD-L1 expression was also downregulated. Our results demonstrate that pazopanib inhibits the Erk/b-catenin pathway, suggesting this pathway might be involved in increased DC activation. Similar results were confirmed in DCs differentiated from mRCC patients during pazopanib treatment. In treated patients pazopanib appeared to enhance a circulating CD4þ T-cell population that expresses CD137 (4-1BB). These results suggest that a potentially exploitable immunomodulatory effect induced by pazopanib could improve responses of patients with mRCC in customized protocols combining TKIs with ICI immunotherapy
2018
RCC; TKI; dendritic cells; pazopanib
01 Pubblicazione su rivista::01a Articolo in rivista
TK inhibitor pazopanib primes DCs by downregulation of the β-catenin pathway / Zizzari, ILARIA GRAZIA; Napoletano, Chiara; Botticelli, Andrea; Caponnetto, Salvatore; Calabro', Fabio; Gelibter, ALAIN JONATHAN; Rughetti, Aurelia; Ruscito, Ilary; RAHIMI KOSHKAKI, Hassan; Ernesto, Rossi; Giovanni, Schinzari; Marchetti, Paolo; Nuti, Marianna. - In: CANCER IMMUNOLOGY RESEARCH. - ISSN 2326-6066. - STAMPA. - 6:6(2018), pp. 711-722. [10.1158/2326-6066.CIR-17-0594]
File allegati a questo prodotto
File Dimensione Formato  
Zizzari_TK Inhibitor-Pazopanib_2018.pdf

accesso aperto

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 1.48 MB
Formato Adobe PDF
1.48 MB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1100735
Citazioni
  • ???jsp.display-item.citation.pmc??? 33
  • Scopus 46
  • ???jsp.display-item.citation.isi??? 42
social impact